Cardiac MRI Biomarker Testing (GCC 1618)

Inclusion Criteria:

Breast cancer patients who are undergoing internal mammary lymph node radiation which is the investigators institutional policy for patients with axillary lymph node involvement
Clinical AJCC (AJCC, 7th ed.) II, IIIA or IIIB with non-operable disease or those who refuse surgery who are recommended concurrent chemoradiation. Patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor are eligible.
Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure
Patients who have received systemic treatment (up to 4 cycles of induction chemotherapy, or up to 6 months of targeted therapy) and are rendered candidate for concurrent chemoradiation are also eligible
Patients with recurrent disease overlapping or in close proximity to heart getting hypofractionated or conventionally fractionated proton therapy alone.
Intensity modulated radiotherapy, 3-D conformal radiotherapy, electron radiotherapy, and proton radiotherapy will be permitted.
Patients who develop local or nodal recurrence after surgery and rendered candidate for definitive concurrent chemoradiation are also eligible.
The patient must give protocol-specific consent on an IRB approved consent form prior to completion of protocol specific testing/procedures.
18 years of age or older.

Exclusion Criteria:

Pregnant/breast feeding patients or those not willing to undertake contraception if of child-producing potential while on study
Patients with Stage IV disease
Patients with contraindications to MRI examination (e.g. gadolinium allergies/reactions, metallic implants, incompatible implanted electronic/cardiac devices, over scanner weight tolerance etc.)
Patients with hepatorenal syndrome
Patients with Chronic Kidney Disease defined as eGFR <30 ml/min
Patients unable to lie supine for 30 minutes for MRI examination
Patients having undergone prior radiation therapy to the chest